Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
NCT ID: NCT03362112
Last Updated: 2022-04-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1713 participants
OBSERVATIONAL
2015-01-30
2017-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Relevant Influencing Factors of Glycemic Control in Patients With Diabetes
NCT05854862
Neutrophil-lymphocyte and Platelet-lymphocyte Ratios and Their Relations to Vascular Comlications and Glycemic Control in Patients With Type 2 Diabetes Attending The Diabetes Center of Assiut University Hospitals
NCT06073756
Atherothrombosis Markers in Diabetics
NCT02898467
Can Platelets/Lymphocytes Rate Be New Serological Index for Prognosis of Coronary Heart Disease Complicated With Impaired Glucose Tolerance: Basic Principles and Experimental Design
NCT02149056
The Effect and Mechanism of MMP-9 in Inducing Atherosclerosis
NCT04424706
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Patients are pregnant.
3. Patients with an acute infection.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing First Hospital, Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
References
Explore related publications, articles, or registry entries linked to this study.
Hu Y, Li TT, Zhou W, Lu TT, Li FF, Ding B, Liu BL, Xie XJ, Ma JH. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease. Diabetes Res Clin Pract. 2019 Apr;150:194-201. doi: 10.1016/j.diabres.2019.03.026. Epub 2019 Mar 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENDO20171130-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.